EUVIMEDEUVIMED entdecken
Crossref

Transient receptor potential channel activation targets multiple stages of the schistosome parasite

Shashank Kulkarni iD, Sang-Kyu Park iD, Youssef Hamway iD, Lukas Friedrich iD, Jesko Kaiser, Evgeny G Chulkov iD, Claudia M Rohr iD, Cécile Häberli, Martin Horn iD, Tobias Hyun Ho Bäurle iD, Mario Pellegatti iD, Gary Grosser iD und 13 weitere

Science Translational Medicine · 2026

DOI: 10.1126/scitranslmed.aed8353 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, 2026. Verfasst von Shashank Kulkarni und 24 weiteren Autor:innen. Beteiligte Einrichtung: EMD Serono Research and Development Institute Inc. (a Business of Merck KGaA., Darmstadt, Germany), Billerica, MA, USA. Hauptthemen laut MEDLINE: Transient Receptor Potential Channels, Life Cycle Stages, Schistosoma mansoni, Schistosoma. Die Arbeit nennt 55 Literaturangaben. Gefördert von: Deutsches Zentrum für Infektionsforschung, NIH, Merck KGaA Darmstadt Germany.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Schistosomiasis, a neglected tropical disease caused by infection with parasitic blood flukes of the genus Schistosoma , affects more than 250 million people worldwide. Currently, patients rely on a single medicine, praziquantel (PZQ), discovered half a century ago. To combat drug resistance and reach elimination of the schistosome parasite, alternative drugs to PZQ are required that treat and prevent disease. Here, we describe a drug candidate, M5493, with potent activity against multiple parasite life cycle stages. The target is a parasite transient receptor potential ion channel, distinct from the target of PZQ. To circumvent its limited bioavailability, the active agent was converted to prodrug M5493, which displayed robust activity against the schistosome parasite at doses as low as 5 milligrams per kilogram in mice infected with Schistosoma mansoni . Unlike the benzodiazepine meclonazepam, which displays clinical antihelminthic activity through the same target, M5493 showed no sedating side effects given that it did not engage GABA A receptors. Overall, this compound has the potential to provide single-dose treatment, broad-spectrum efficacy against schistosome parasites at different life cycle stages, and transmission blocking activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transient Receptor Potential ChannelsLife Cycle StagesSchistosoma mansoniSchistosomaAnimalsMicePraziquantelHumansProdrugs

Substanzen

Transient Receptor Potential ChannelsPraziquantelProdrugs

Autor:innen und Institutionen

  • EMD Serono Research and Development Institute Inc. (a Business of Merck KGaA., Darmstadt, Germany), Billerica, MA, USA.
  • Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Munich, Germany.
  • Center for Global Health, TUM School of Medicine, Technical University of Munich, Munich, Germany.
  • German Center for Infection and Research (DZIF), Partner site Munich, Munich, Germany.
  • Computational Chemistry and Biology, Global Research and Development, Discovery Technologies, the Healthcare Business of Merck KGaA, Darmstadt, Germany.

ORCID-Profile: Shashank Kulkarni, Sang-Kyu Park, Youssef Hamway, Lukas Friedrich, Evgeny G Chulkov, Claudia M Rohr, Martin Horn, Tobias Hyun Ho Bäurle, Mario Pellegatti, Gary Grosser, Rana Afshar, Andreas Becker, Nico Alexander Mell, Floriane Lignet, Philip Hewitt, Christian Brenneis, Jan Dvorak, Clarissa Prazeres da Costa, Jennifer Keiser, Jonathan S Marchant, Thomas Spangenberg

Förderung

  • Deutsches Zentrum für Infektionsforschung
  • NIH
  • Merck KGaA Darmstadt Germany
  • The healthcare business of Merck KGaA, Darmstadt, Germany

Zitieren

APA

Kulkarni, S., Park, S. K., Hamway, Y., Friedrich, L., Kaiser, J., Chulkov, E. G., Rohr, C. M., Häberli, C., Horn, M., Bäurle, T. H. H., Pellegatti, M., Grosser, G., Becker, A., Afshar, R., Becker, A., Mell, N. A., Lignet, F., Hewitt, P., Hansen, A., …, & Spangenberg, T. (2026). Transient receptor potential channel activation targets multiple stages of the schistosome parasite. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aed8353

Vancouver

Kulkarni S, Park SK, Hamway Y, Friedrich L, Kaiser J, Chulkov EG, et al. Transient receptor potential channel activation targets multiple stages of the schistosome parasite. Science Translational Medicine. 2026. doi:10.1126/scitranslmed.aed8353

BibTeX
@article{Kulkarni2026,
  author = {Kulkarni, Shashank and Park, Sang-Kyu and Hamway, Youssef and Friedrich, Lukas and Kaiser, Jesko and Chulkov, Evgeny G and Rohr, Claudia M and Häberli, Cécile and Horn, Martin and Bäurle, Tobias Hyun Ho and Pellegatti, Mario and Grosser, Gary and Becker, Axel and Afshar, Rana and Becker, Andreas and Mell, Nico Alexander and Lignet, Floriane and Hewitt, Philip and Hansen, Annika and Brenneis, Christian and Dvorak, Jan and da Costa, Clarissa Prazeres and Keiser, Jennifer and Marchant, Jonathan S and Spangenberg, Thomas},
  title = {Transient receptor potential channel activation targets multiple stages of the schistosome parasite},
  journal = {Science Translational Medicine},
  year = {2026},
  doi = {10.1126/scitranslmed.aed8353}
}
Kostenlos starten →